Tadalafil Tablet, Film Coated
Product Images NDC 51655-487

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 51655-487). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northwind Health Company, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (51655 487 52)

Label for Tadalafil Tablets USP 5 mg, film-coated oral tablets by Northwind Health Company, LLC. The package contains 30 tablets with a prescription-only designation. Storage instructions specify 25°C with permitted excursions, and warnings include keeping out of reach of children and not splitting tablets.*

FDA Label Image

Figure (Tadalafil Figure1)

A set of four line graphs depicting the difference in blood pressure (BP) measurements between Tadalafil and placebo over time (hours). The charts show standing systolic BP, standing diastolic BP, supine systolic BP, and supine diastolic BP, with error bars indicating variability in measurements up to 96 hours.*

FDA Label Image

Figure (Tadalafil Figure2)

A graph showing the effect of Tadalafil 20 mg with doxazosin 8 mg versus placebo with doxazosin 8 mg on standing and supine systolic blood pressure over 24 hours post-dose. The top plot displays standing systolic blood pressure changes, and the bottom plot displays supine systolic blood pressure changes, with time in hours on the x-axis and blood pressure in mmHg on the y-axis.*

FDA Label Image

Figure (Tadalafil Figure3)

A line graph showing changes in systolic blood pressure (mmHg) over time (hours) after administration of tadalafil or placebo. The graph compares the effects of 20 mg tadalafil administered at 08:00 and 20:00, each combined with 8 mg doxazosin at 08:00, against placebo with 8 mg doxazosin. The y-axis represents systolic BP changes, and the x-axis represents time up to 12 hours post-dose.*

FDA Label Image

Figure (Tadalafil Figure4)

A line graph depicting plasma tadalafil concentration (µg/L) over time (hours) for a single 20-mg dose, a single 5-mg dose, and once-daily 5-mg dosing for five consecutive days. The graph shows concentration peaks and declines with error bars at multiple time points up to 120 hours.*

FDA Label Image

Figure 5 (Tadalafil Figure5)

A line graph illustrating the change from baseline in IPSS total score over a 12-week treatment period. The graph compares tadalafil 5 mg tablets to placebo, showing greater reductions in score for the tadalafil group across 4, 8, and 12 weeks. The x-axis represents treatment duration in weeks, and the y-axis shows change from baseline in IPSS total score.*

FDA Label Image

Figure 6 (Tadalafil Figure6)

A line graph comparing the change from baseline in IPSS total score over 12 weeks of treatment between tadalafil 5 mg and placebo. The vertical axis shows change from baseline, and the horizontal axis shows the duration of treatment in weeks, with data points at 0, 1, 4, 8, and 12 weeks. Tadalafil shows a greater reduction in score compared to placebo, with statistical significance indicated at certain points.*

FDA Label Image

Figure 7 (Tadalafil Figure7)

A line graph showing the least squares mean change from baseline over 26 weeks of therapy for Tadalafil/Finasteride versus Placebo/Finasteride groups. The graph depicts measurements at weeks 0, 4, 12, and 26, with Tadalafil/Finasteride showing greater negative change values compared to Placebo/Finasteride, indicating different treatment responses over time.*

FDA Label Image

Figure 8 (Tadalafil Figure8)

A line graph showing the change from baseline in IPSS Total Score over a 12-week treatment duration. It compares Tadalafil 5 mg (solid line with circles) with placebo (dashed line with triangles), demonstrating a greater decrease in IPSS score over time for Tadalafil. Statistical significance is indicated at 12 weeks (p<0.01).*

FDA Label Image

Chemical Structure (Tadalafil Structure)

Chemical structure of Tadalafil showing the arrangement of its atoms and bonds, including aromatic rings and functional groups characteristic of this active ingredient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.